| scholarly article | Q13442814 |
| P2093 | author name string | Vicente Valero | |
| Ihor Pidhorecky | |||
| Aurelio Bartolome Castrellon | |||
| Luis Estuardo Raez | |||
| P2860 | cites work | Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. | Q54516956 |
| The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. | Q54615889 | ||
| Triple-negative breast cancer: an update on neoadjuvant clinical trials | Q35725961 | ||
| Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials | Q36337755 | ||
| Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer | Q36385670 | ||
| Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents | Q37251187 | ||
| Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes | Q37269261 | ||
| Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design | Q37418501 | ||
| Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer | Q37601722 | ||
| Beyond triple-negative breast cancer: the need to define new subtypes | Q37782088 | ||
| Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer | Q38012010 | ||
| Neoadjuvant treatments for triple-negative breast cancer (TNBC). | Q38046580 | ||
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | Q38188183 | ||
| Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients | Q38240441 | ||
| Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. | Q38393045 | ||
| How basal are triple-negative breast cancers? | Q40105023 | ||
| Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status | Q42458660 | ||
| The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes | Q42511189 | ||
| Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation | Q42511967 | ||
| Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). | Q45056867 | ||
| Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological features | Q45181661 | ||
| Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer | Q46771645 | ||
| Preoperative chemotherapy for women with operable breast cancer | Q24245281 | ||
| The epidemiology of triple-negative breast cancer, including race | Q24289471 | ||
| Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer | Q26740393 | ||
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Q27851705 | ||
| PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions | Q28071345 | ||
| Triple-Negative Breast Cancer | Q29391607 | ||
| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies | Q29617680 | ||
| American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer | Q30494798 | ||
| Rare breast cancer: 933 adenoid cystic carcinomas from the National Cancer Data Base | Q30596512 | ||
| Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial | Q33415041 | ||
| Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40 | Q33416887 | ||
| Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases | Q33715354 | ||
| PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). | Q33883406 | ||
| Triple-negative breast cancer: role of specific chemotherapy agents | Q33900930 | ||
| Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer | Q34625335 | ||
| Triple-negative breast cancer: clinical features and patterns of recurrence | Q34658655 | ||
| Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes | Q35021314 | ||
| Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer | Q35114444 | ||
| Incidence of acute myeloid leukemia after breast cancer | Q35640784 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | neoadjuvant chemotherapy | Q108855558 |
| carboplatin | Q415588 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 324 | |
| P577 | publication date | 2017-03-17 | |
| P1433 | published in | Oncology reviews | Q26841967 |
| P1476 | title | The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer | |
| P478 | volume | 11 |
| Q47110708 | Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. |
| Q41555731 | Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer. |
| Q90608087 | Genotoxicity of cisplatin and carboplatin in cultured human lymphocytes: a comparative study |
| Q64268061 | Interaction of tumor-associated macrophages and cancer chemotherapy |
| Q57070548 | Mechanism of HN‑3 cell apoptosis induced by carboplatin: Combination of mitochondrial pathway associated with Ca2+ and the nucleus pathways |
| Q90465739 | Oxidative stress induced by carboplatin promotes apoptosis and inhibits migration of HN-3 cells |
| Q55353691 | Recent Advances in the Treatment of Breast Cancer. |
| Q64243646 | Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response |
| Q64119664 | Targeting stem cells in the realm of drug-resistant breast cancer |
Search more.